Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

pharmaphorum

JANUARY 11, 2021

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market. Meanwhile the as-yet unnamed oncology company will spin off under the leadership of bluebird’s current chief executive Nick Leschly. million price tag.

Gene Therapy 60

Gene Therapy Gene Genetic Disease Manufacturing 60

Drug Discovery World

JUNE 14, 2023

We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours. You can even look at it in from a broader perspective of what is the next breakthrough in oncology. I’ve been with a company for more than five years now.

Research 52

Research Engineer In-Vivo Production 52

XTalks

OCTOBER 12, 2022

We [Philips Pharma Solutions, formerly BioTel Research] have successfully ran multi-site DCE-MRI trials,” said Edward Ashton, PhD, VP, Oncology Imaging, Philips Pharma Solutions. An Example of an Anti-Angiogenic Therapy in Oncology. An Example of an Anti-Vascular Therapy in Oncology. Introduction to Perfusion Imaging.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. The Immuno-STAT Platform: Cell-Independent Protein Design. The Immuno-STAT Molecules. The T cell epitope is usually an 8 – 10 amino acid peptide.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Delveinsight

FEBRUARY 25, 2021

Combining immuno-oncology treatments such as checkpoint inhibitors with other cancer-killing drugs is considered a remarkable strategy for enhancing the response rate to immunotherapy. Increasing the immune system’s T cells to enhance cancer-destroying capabilities.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

NOVEMBER 13, 2023

Jens Fischer, PhD, Program Manager, Large Molecule Research Therapeutic Modalities, Roche Pharma Research and Early Development (pRED), on: ‘ Bispecific and next-generation antibodies for non-oncology indications such as ophthalmologic and neurologic diseases’. It is called, ‘An unexpected future for immune oncology therapies?’

Protein 59

Protein Antibody Engineer Scientist 59